Stay updated with breaking news from Clinical Value. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The goal in highlighting this development is to attempt to raise awareness of the critical issue of information overload and the need for multiple involved parties to actively and aggressively search for appropriate, effective, and fiscally rational solutions.
Juventas Cell Therapy Ltd. announces China National Medical Product Administration (NMPA) has approved its New Drug Application (NDA) for Inatic...
/PRNewswire/ -- At the 2023 ASCO annual meeting, investigators from OneOncology's clinical team will present Oral Abstracts using real-world data to evidence...
The Chinese government's past efforts to reform its pharmaceutical industry's regulatory framework can be traced back to the 2015 Opinions on…
With the government implementing more reform initiatives, the National Medical Products Administration NMPA on May 9, 2022, published new draft Implementing Regulations, which will add a total of 101 new articles to the latest version of the Law.